Detection and Diagnosis of Pancreatic Carcinoma
胰腺癌的检测和诊断
基本信息
- 批准号:8465742
- 负责人:
- 金额:$ 24.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-09-09 至 2015-04-30
- 项目状态:已结题
- 来源:
- 关键词:Abdominal PainAffinityAntibodiesAntibody SpecificityAntigensBenignBiochemicalBiological AssayBiological MarkersBloodBody Weight decreasedCancer EtiologyCarcinomaCessation of lifeClinicalClinical TrialsDataData CorrelationsDetectionDevelopmentDiagnosisDiagnosticDiscriminationDiseaseDisease ProgressionEarly DiagnosisEnzyme ImmunoassayEpitopesEvaluationFundingGenerationsGlycoproteinsGoalsGrantHepatobiliaryHistocompatibility TestingHistologicIcterusImageImmunoassayIn VitroIndividualInvestigationLaboratoriesLesionLiquid substanceLocationMalignant - descriptorMalignant NeoplasmsMalignant neoplasm of pancreasMass Spectrum AnalysisMeasuresMedical AssistanceMindModificationMonoclonal AntibodiesMucinsMusNatureNormal tissue morphologyObservational StudyOperative Surgical ProceduresOutcomePancreasPancreatic DiseasesPancreatic Intraepithelial NeoplasiaPancreatic carcinomaPancreatitisPatientsPeptidesPerformancePhage DisplayPopulationPredictive ValueProceduresPropertyPublicationsPublishingRelapseReportingResearchResearch ProposalsRoleSamplingSerumSpecificitySpecimenStagingStudy SectionSurveillance ProgramSymptomsSystemic TherapyTestingTherapeutic InterventionTimeTissuesTranslatingUnited StatesWomanWorkbasecancer diagnosiscell typediagnostic accuracydisease diagnosisfollow-uphigh riskimprovedmenmortalityoutcome forecastpancreatic neoplasmprogramsprospectivepublic health relevanceresponsescreeningstatisticstumortumor growth
项目摘要
DESCRIPTION (provided by applicant): The objective of this research proposal is the development and evaluation of immunoassays having clinical utility for the "early" detection and diagnosis of pancreatic carcinoma. In the year 2009, an estimated 42,000 new cases of pancreatic carcinoma will be diagnosed in the United States. Pancreatic carcinoma is the tenth most common form of cancer in men and women today, yet it is the fourth leading cause of cancer deaths. The most common symptoms of the disease, jaundice, abdominal pain, and weight loss, together with other presenting factors are nonspecific in nature. Thus, diagnosing pancreatic carcinoma at an early stage of tumor growth is difficult at best, requiring considerable suspicion and extensive diagnostic work-up, up to and including exploratory surgery. Our laboratory has developed and characterized the PAM4 monoclonal antibody (murine, chimeric and humanized versions), providing evidence as to its potential for clinical detection, imaging and therapy of pancreatic carcinoma. Our recent developments employing an in vitro enzyme immunoassay to quantitate PAM4-reactive antigen in the blood of patients, appears quite promising for detection of pancreatic carcinoma and its discrimination from pancreatitis, as well as other cancers and normal individuals. Early detection and diagnosis of pancreatic carcinoma, as well as appropriate staging of the disease, would almost certainly provide a survival advantage. With this in mind, we intend to further develop and assess the ability of the PAM4-based immunoassays, both immunohistochemical detection in tissue specimens and enzyme immunoassay to detect and quantitate the antigen in both serum and pancreatic fluids, to provide "early" detection and diagnosis at a time-point when therapeutic intervention may have better opportunity for successful outcome. The specific aims of this project are: 1. To evaluate the performance profile of the PAM4-Immunoassay for diagnostic accuracy; 2. To evaluate the clinical utility of the PAM4-Immunoassay for a-accurate diagnosis of patients presenting with symptoms suggestive of pancreatic cancer; b- early detection of pancreatic carcinoma in asymptomatic individuals at high risk for pancreatic cancer; c- assessment of tumor response or early detection of relapse; 3. To evaluate the nature of the antigen to which PAM4 is reactive.
描述(由申请人提供):本研究计划的目的是开发和评估具有“早期”检测和诊断胰腺癌临床效用的免疫测定。在2009年,估计有42,000例新的胰腺癌病例将在美国被诊断出来。胰腺癌是当今男性和女性中第十大最常见的癌症形式,但它是癌症死亡的第四大原因。该疾病最常见的症状,黄疸、腹痛、体重减轻,以及其他表现因素在本质上是非特异性的。因此,在肿瘤生长的早期诊断胰腺癌是很困难的,需要大量的怀疑和广泛的诊断检查,甚至包括探查性手术。我们的实验室已经开发并鉴定了PAM4单克隆抗体(小鼠,嵌合和人源化版本),为其在胰腺癌的临床检测,成像和治疗方面的潜力提供了证据。我们最近的研究进展是采用体外酶免疫分析法来定量患者血液中的pam4反应性抗原,这对于胰腺癌的检测及其与胰腺炎的区分,以及其他癌症和正常个体的区分,似乎很有希望。胰腺癌的早期发现和诊断,以及适当的疾病分期,几乎肯定会提供生存优势。考虑到这一点,我们打算进一步发展和评估基于pam4的免疫测定的能力,包括组织标本中的免疫组化检测和酶免疫测定,以检测和定量血清和胰液中的抗原,在治疗干预可能有更好成功机会的时间点提供“早期”检测和诊断。本项目的具体目标是:1。评估pam4免疫分析法的诊断准确性;2. 评估pam4免疫分析法在准确诊断有胰腺癌症状患者中的临床应用;B -胰腺癌无症状高危人群早期发现胰腺癌;C -评估肿瘤反应或早期发现复发;3. 评价PAM4能反应的抗原的性质。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DAVID V GOLD其他文献
DAVID V GOLD的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DAVID V GOLD', 18)}}的其他基金
相似海外基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 24.82万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 24.82万 - 项目类别:
Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
- 批准号:
61319 - 财政年份:2020
- 资助金额:
$ 24.82万 - 项目类别:
Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10013588 - 财政年份:2020
- 资助金额:
$ 24.82万 - 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
- 批准号:
20K07009 - 财政年份:2020
- 资助金额:
$ 24.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
- 批准号:
10603473 - 财政年份:2020
- 资助金额:
$ 24.82万 - 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
- 批准号:
2342674 - 财政年份:2020
- 资助金额:
$ 24.82万 - 项目类别:
Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
- 批准号:
10117194 - 财政年份:2020
- 资助金额:
$ 24.82万 - 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10115604 - 财政年份:2020
- 资助金额:
$ 24.82万 - 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
- 批准号:
10294224 - 财政年份:2018
- 资助金额:
$ 24.82万 - 项目类别: